Lilly's SVP of Talent said diverse backgrounds, skills and perspectives "fuel" innovation and "strengthen the understanding ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly (NYSE: LLY) has been one of the top-performing healthcare megacap stocks of the past decade. Eli Lilly is ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of ...

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

That’s up from a rate of 9.9 prescriptions per 100,000 in 2023, the first full year that Wegovy was available to children ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Discover how biotechs and big pharma are developing novel treatments for high cholesterol with a range of different targets.

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...